Late-Breaking Abstracts

Late-Breaking Abstracts - Clinical Only (LBA)

Late-breaking Abstracts no longer have an application requirement.
If a Late-breaking Abstract is not accepted, it will not be presented at the meeting.

Abstract Dates Abstract FAQsAbstract Reference Guide

SITC 2025 is your chance to have your late-breaking abstract reviewed by a committee of IO leaders.

Late-Breaking Abstracts – Clinical Only (LBA) are reviewed by the LBA Review Committee and are selected for presentation by the LBA Review Committee and the Annual Meeting organizers. LBAs may be selected for oral presentation in a Clinical Abstract Session or a regular plenary or concurrent session. LBAs are considered for oral presentation based on the abstract content, review scores and feedback, whether the abstract is truly late-breaking, and if the abstract serves the needs and interest of the SITC audience.

Elizabeth Jaffee, MD

Elizabeth M. Jaffee, MD, FAIO, FAACR, FACP, FAAAS
Sidney Kimmel Cancer Center at Johns Hopkins

Patricia LoRusso, DO, PhD

Patricia LoRusso, DO
Yale School of Medicine 

Jason Luke, MD, PhD

Jason J. Luke, MD, FACP
University of Pittsburgh 

Aurelien Marabelle, MD, PhD

Aurelien Marabelle, MD, PhD
Gustave Roussy 

Thomas Marron, MD, PhD

Thomas Marron, MD, PhD
Mount Sinai

Lillian Siu, MD

Lillian L. Siu, MD
Princess Margaret Cancer Center, University Health Network 

Ryan Sullivan, MD 

Ryan J. Sullivan, MD 
Harvard Medical School, Massachusetts General Hospital  

Late-Breaking Abstract - Clinical Only (LBA) Information and Eligibility

Late-breaking Abstract (LBA) submission is solely for abstracts with late-breaking data from interventional clinical trials in humans and not for abstracts submitted “late.” The LBA deadline is not intended to be an extension of the general submission deadline. LBAs highlight novel and practice-changing in-human clinical studies and only apply to data that would have not otherwise have been presented as an abstract at the 40th Anniversary Annual Meeting.

  Authors of LBAs do not need to submit an application or a place-holder abstract. LBAs should be submitted during the LBA submission period, from July 16–Sept. 15 at 5 p.m. PT.

If a Late-breaking Abstract is not accepted, it will not be published or presented at the meeting. There is not an option for it to be considered as a Regular/YIA Abstract.

 Late-Breaking Abstracts - Clinical Only (LBAs)

Clinical Abstracts: LBAs must address interventional clinical trials in humans. LBAs addressing basic science or translational data with no in-human studies will not be accepted. LBAs may contain data from preclinical studies, but they must also include clinical data from in-human trials. Authors will need to justify why the abstract is considered late-breaking. Clinical trial LBAs should be submitted during the LBA submission period, from July 16–Sept. 15 at 5 p.m. PT.

 Late-Breaking Abstracts - Clinical Only (LBAs)

Guidelines for Basic or Translational Abstracts: Because LBAs will be limited to clinical studies, authors submitting an abstract of a basic science or translational study must submit their abstract by the Regular/YIA Abstract deadline of June 26 at 5 p.m. PT. If some results from the study are not available before the abstract submission deadline, authors are encouraged to submit an abstract by the deadline and include the new data in their abstract presentation.

Examples of acceptable LBAs include the following (in each case, results were not available or significant by the regular abstract submission deadline):

  • Results of a practice-changing prospective Phase III clinical trial
  • Phase II study showing anti-tumor activity in a novel context
  • An early in-human clinical trial with novel proof-of-principle data

LBAs are considered for oral and poster presentation slots on either Friday, Nov. 7 or Saturday, Nov. 8. The data in the abstract must not be published prior to SITC 2025.

LBA Oral Presentation Opportunities

LBAs are considered for, but not limited to, oral abstract presentations during the LBA Sessions from 11:30 a.m.–12:15 p.m. on Friday, Nov. 7, 2025 and 1:45–3 p.m. on Saturday, Nov. 8, 2025.

 New in 2025 - Additional Oral Presentation for Clinical Abstracts

This year there will be additional oral presentation opportunities for clinical abstracts. Clinical oral abstract sessions will be held Friday, Nov. 7 from 11:30 a.m.–12:15 p.m. ET and Saturday, Nov. 8 from 1:45–3 p.m. ET (session times subject to change).

Late-Breaking Abstracts - Clinical Only (LBA) Additional Fields

Late-Breaking Abstracts – Clinical Only (LBA) submission is solely for abstracts with late-breaking data from interventional clinical trials in humans and not for abstracts submitted “late”. LBAs will need to include the following information in their abstract:

  • Closure date of the study
  • Primary clinical endpoint for analysis
  • Type of analysis
  • Provide an explanation why the abstract should be considered for late-breaking submission

This information will not be included in the JITC Abstract Supplement, but will be provided to reviewers during the review process.

Important Late-Breaking Abstract - Clinical Only (LBA) Dates

July 16, 2025
LBA Submission Site Opens

Sept. 15, 2025
LBA Submission Site Closes at 5 p.m. PT

Sept. 30, 2025
LBA Notifications Sent

Oct. 7, 2025
LBA Presentation Acceptance Confirmation Due/Deadline for LBA Withdrawals (Withdrawals must be made by emailing education@sitcancer.org to Indicate a Withdrawal)

Oct. 30, 2025
LBA Title and Author Information Released at 9 a.m. ET

Nov. 7, 2025
Embargo Lifted and Full Regular and LBA Made Public at 9 a.m. ET. All accepted abstract are available in the JITC Supplement

Nov. 5–9, 2025
40th Anniversary Annual Meeting & Pre-Conference Programs

Feb. 2026
Final Supplement Published in JITC